Affinity Asset Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Affinity Asset Advisors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-125,969	Closed	-$1.54M	–	110
2023 Q4	$1.54M	Sell	125,969 -152,323	-55%	-$1.39M	0.28%	60
2023 Q3	$2.68M	Buy	278,292 +100,000	+56%	+$1.02M	0.75%	40
2023 Q2	$1.6M	Sell	178,292 -30,000	-14%	-$277K	0.56%	41
2023 Q1	$1.64M	Buy	208,292 +20,000	+11%	+$149K	0.54%	45
2022 Q4	$1.27M	Buy	188,292 +91,974	+95%	+$493K	0.5%	48
2022 Q3	$1.4M	Buy	+96,318	New	+$1.35M	0.39%	47
2021 Q3	–	Sell	-50,000	Closed	-$1.2M	–	84
2021 Q2	$1.2M	Sell	50,000 -50,000	-50%	-$1.31M	0.43%	48
2021 Q1	$2.57M	Buy	100,000 +55,000	+122%	+$1.45M	0.87%	33
2020 Q4	$855K	Buy	+45,000	New	+$772K	0.45%	46

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Affinity Asset Advisors's KALV Position: Q1 2024 in Review

Affinity Asset Advisors sold out of KalVista Pharmaceuticals (KALV) in Q1 2024, closing a stake of 125,969 shares — an estimated $1.54M sold.

Affinity Asset Advisors first reported a position in KALV in Q4 2020 and held it in 9 quarters. The position peaked at $2.68M in Q3 2023. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2024.

Affinity Asset Advisors reported no remaining KalVista Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Affinity Asset Advisors sold 125,969 KalVista Pharmaceuticals shares in Q1 2024, an estimated $1.54M.
Affinity Asset Advisors first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 9 quarters.
Affinity Asset Advisors's KalVista Pharmaceuticals position peaked at $2.68M in Q3 2023.
128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2024.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.